MP Biomedicals is acquiring New Zealand-based protein biologics manufacturing company ICPbio International. MP Biomedicals claims the acquisition means it will be able to add serum protein products for research, biopharmaceutical, and diagnostic applications to its existing lines of life science, fine chemical, and diagnostic products and services.
ICPbio uses what it calls state-of-the-art chromatographic extraction to isolate high purity intact proteins. The firm’s current product portfolio includes bovine-derived thrombin, transferrin, albumin, and IgG.
“We feel that this world-class protein-separation platform provides the manufacturing organization resources needed for MP Biomedicals to more fully serve customer demands for quality, low-risk serum protein materials collected and produced in the pristine environment of New Zealand,” comments Milan Panic, chairman and CEO at MP Biomedicals.